nucleosome assembly protein 1 like 1 pseudogene 2Genealiases: []
Q-omics provides the consensus-scored NAP1L1P2 profile across patient tissues and cancer cell-line models. NAP1L1P2 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, NAP1L1P2 is differentially expressed in 4, with the highest sampling consensus in HNSC. Additionally, NAP1L1P2 RNA expression shows 6,338 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight BLCA, HNSC, and STAD as cancer lineages where NAP1L1P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NAP1L1P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NAP1L1P2 survival associations across molecular data types. NAP1L1P2 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NAP1L1P2 RNA expression–survival associations across cancer types. High NAP1L1P2 expression shows unfavorable associations in MESO, ESCA, KIRC and KIRP, but favorable associations in BLCA and READ. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify BLCA as the clearest survival context for NAP1L1P2 RNA expression.
This table summarizes NAP1L1P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for NAP1L1P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NAP1L1P2 shows lower tumor expression in KICH and higher tumor expression in HNSC, CHOL and ESCA. The HNSC box plot shows higher NAP1L1P2 RNA expression in tumor versus normal tissue (log2 FC = +0.030, t-test p = .008).
This table shows molecular features associated with NAP1L1P2 in patient tissues and cancer cell lines. In patient samples, NAP1L1P2 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
